Blog

Location: Cambridge

Robert Weisskoff, PhD

Robert Weisskoff, Senior Partner, joined F-Prime in 2004.  Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents.

Robert holds a PhD in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa.

Robert serves on the Board of Directors of Adela, Affinia Therapeutics, Countable Labs, Plasmagen Biosciences, RareCyte, Shinobi Therapeutics, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Caribou Biosciences (NASDAQ: CRBU), Farapulse (acquired by Boston Scientific), Ikano Therapeutics (acquired by UCB), Laurus Labs (NSE: LAURUSLABS), Structure Therapeutics (NASDAQ: GPCR), Surface Oncology (NASDAQ: SURF), Tetraphase (NASDAQ: TTPH), Transave (NASDAQ: INSM), Topaz (acquired by Sanofi Pasteur), ViewRay (NASDAQ: VRAY) and Xilio Therapeutics (NASDAQ: XLO).

Stephen Knight, MD

Stephen Knight joined F-Prime in 2003 where he serves as President and Senior Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Leyden Labs, Paradigm, Quarry Thera, and Xaira Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Quantum Circuits, Inc. (acquired by D-Wave), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA), and Semma Therapeutics (acquired by Vertex).

Prior to joining F-Prime, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an MD from the Yale University School of Medicine, and an MBA from the Yale School of Organization and Management and received a BS in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.